A citation-based method for searching scientific literature

Michael A Henderson, Bryan H Burmeister, Jill Ainslie, Richard Fisher, Juliana Di Iulio, B Mark Smithers, Angela Hong, Kerwin Shannon, Richard A Scolyer, Scott Carruthers, Brendon J Coventry, Scott Babington, Joao Duprat, Harald J Hoekstra, John F Thompson. Lancet Oncol 2015
Times Cited: 96







List of co-cited articles
614 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
975
39

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
Mark B Faries, John F Thompson, Alistair J Cochran, Robert H Andtbacka, Nicola Mozzillo, Jonathan S Zager, Tiina Jahkola, Tawnya L Bowles, Alessandro Testori, Peter D Beitsch,[...]. N Engl J Med 2017
570
36

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino,[...]. N Engl J Med 2018
739
35

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon,[...]. N Engl J Med 2017
641
33

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards,[...]. N Engl J Med 2016
738
32

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Bryan H Burmeister, Michael A Henderson, Jill Ainslie, Richard Fisher, Juliana Di Iulio, B Mark Smithers, Angela Hong, Kerwin Shannon, Richard A Scolyer, Scott Carruthers,[...]. Lancet Oncol 2012
158
31

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards,[...]. Lancet Oncol 2015
711
29

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur,[...]. CA Cancer J Clin 2017
839
29

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
28

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
Shefali Agrawal, John M Kane, Beverly A Guadagnolo, William G Kraybill, Matthew T Ballo. Cancer 2009
90
27

Final version of 2009 AJCC melanoma staging and classification.
Charles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, John F Thompson, Michael B Atkins, David R Byrd, Antonio C Buzaid, Alistair J Cochran, Daniel G Coit, Shouluan Ding,[...]. J Clin Oncol 2009
26

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, Werner Hohenberger, Norbert Brockmeyer, Carola Berking, Cord Sunderkötter, Martin Kaatz, Klaus-Werner Schulte, Percy Lehmann,[...]. Lancet Oncol 2016
326
26

Final trial report of sentinel-node biopsy versus nodal observation in melanoma.
Donald L Morton, John F Thompson, Alistair J Cochran, Nicola Mozzillo, Omgo E Nieweg, Daniel F Roses, Harold J Hoekstra, Constantine P Karakousis, Christopher A Puleo, Brendon J Coventry,[...]. N Engl J Med 2014
774
21

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
15

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
15

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, Alexandre Reuben, Miles C Andrews, Merrick I Ross, Isabella C Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A Tawbi,[...]. Lancet Oncol 2018
125
15

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, Michael A Davies, Merrick I Ross, Isabella C Glitza, Janice N Cormier, Carol Lewis, Wen-Jen Hwu, Ehab Hanna,[...]. Nat Med 2018
291
15

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
14

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
13

Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.
R J Lee, J F Gibbs, G M Proulx, D R Kollmorgen, C Jia, W G Kraybill. Int J Radiat Oncol Biol Phys 2000
112
12

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A Delman, Lynn E Spitler, Igor Puzanov, Sanjiv S Agarwala,[...]. J Clin Oncol 2015
12

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
12

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Alexander Mm Eggermont, Stefan Suciu, Mario Santinami, Alessandro Testori, Wim Hj Kruit, Jeremy Marsden, Cornelis Ja Punt, François Salès, Martin Gore, Rona MacKie,[...]. Lancet 2008
433
11

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Alexander M M Eggermont, Stefan Suciu, Alessandro Testori, Mario Santinami, Wim H J Kruit, Jeremy Marsden, Cornelis J A Punt, François Salès, Reinhard Dummer, Caroline Robert,[...]. J Clin Oncol 2012
184
11

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
11

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob,[...]. Lancet 2015
771
11

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Lancet Oncol 2016
471
11

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. Lancet 2017
577
11

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux,[...]. J Clin Oncol 2018
112
11

A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06.
Bryan H Burmeister, B Mark Smithers, Elizabeth Burmeister, Kathryn Baumann, Sidney Davis, Hedley Krawitz, Carol Johnson, Nigel Spry. Radiother Oncol 2006
57
17

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.
Charles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, John F Thompson, Shouluan Ding, David R Byrd, Natale Cascinelli, Alistair J Cochran, Daniel G Coit, Alexander M Eggermont,[...]. J Clin Oncol 2010
289
10

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O'Day, Jeffrey Weber, Claus Garbe, Celeste Lebbe, Jean-François Baurain, Alessandro Testori, Jean-Jacques Grob,[...]. N Engl J Med 2011
10

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
10

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski,[...]. Lancet Oncol 2018
94
10

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Christian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, Karolina Sikorska, Bart van de Wiel, Pia Kvistborg, Oscar Krijgsman, Marlous van den Braber, Daisy Philips, Annegien Broeks,[...]. Nat Med 2018
264
10

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.
Andrew J Hayes, Lauren Maynard, Gillian Coombes, Julia Newton-Bishop, Michael Timmons, Martin Cook, Jeffrey Theaker, Judith M Bliss, J Meirion Thomas. Lancet Oncol 2016
61
14

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
C M Balch, S J Soong, J E Gershenwald, J F Thompson, D S Reintgen, N Cascinelli, M Urist, K M McMasters, M I Ross, J M Kirkwood,[...]. J Clin Oncol 2001
9

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
9

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
9

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, Omid Hamid, F Stephen Hodi, Stergios J Moschos, Nikhil I Khushalani, Karl Lewis, Christopher D Lao, Michael A Postow,[...]. N Engl J Med 2018
488
9

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
Georgina V Long, Robyn P M Saw, Serigne Lo, Omgo E Nieweg, Kerwin F Shannon, Maria Gonzalez, Alexander Guminski, Jenny H Lee, Hansol Lee, Peter M Ferguson,[...]. Lancet Oncol 2019
50
18

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Elisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, Chandra Adhikari, Carolien Bierman, Bart A van de Wiel, Richard A Scolyer, Oscar Krijgsman, Karolina Sikorska, Hanna Eriksson,[...]. Lancet Oncol 2019
137
9

Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation.
Daniel T Chang, Robert J Amdur, Christopher G Morris, William M Mendenhall. Int J Radiat Oncol Biol Phys 2006
58
13

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
J M Kirkwood, J G Ibrahim, V K Sondak, J Richards, L E Flaherty, M S Ernstoff, T J Smith, U Rao, M Steele, R H Blum. J Clin Oncol 2000
626
8

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
J M Kirkwood, M H Strawderman, M S Ernstoff, T J Smith, E C Borden, R H Blum. J Clin Oncol 1996
8

The role of adjuvant radiotherapy in the local management of desmoplastic melanoma.
B Ashleigh Guadagnolo, Victor Prieto, Randal Weber, Merrick I Ross, Gunar K Zagars. Cancer 2014
44
18

Radiotherapy influences local control in patients with desmoplastic melanoma.
Tobin Strom, Jimmy J Caudell, Dale Han, Jonathan S Zager, Daohai Yu, C Wayne Cruse, Suroosh S Marzban, Jane L Messina, Andy M Trotti, Vernon K Sondak,[...]. Cancer 2014
38
21

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
8

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M Kirkwood, Vanna Chiarion Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux,[...]. N Engl J Med 2020
48
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.